Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus Acidophilus Cul60

Also known as: Lactobacillus acidophilus CUL60, L. acidophilus CUL60, NCIMB 30157

Overview

Lactobacillus acidophilus CUL60 is a specific strain of *Lactobacillus acidophilus*, a Gram-positive, facultative anaerobic bacterium naturally found in the human gastrointestinal tract and fermented dairy products. It is primarily utilized as a probiotic to support digestive health, modulate gut microbiota, and potentially alleviate gastrointestinal symptoms such such as diarrhea and irritable bowel syndrome (IBS). This strain is frequently incorporated into multi-strain probiotic formulations, notably the LAB4 blend, and has been investigated for its effects on antibiotic-associated diarrhea (AAD), lipid profiles, and IBS. Research on *L. acidophilus* CUL60 is moderately developed, with several randomized controlled trials (RCTs) and systematic reviews/meta-analyses evaluating its efficacy, often in conjunction with other probiotic strains.

Benefits

Lactobacillus acidophilus CUL60 offers several evidence-based benefits, primarily in gut health. For antibiotic-associated diarrhea (AAD), systematic reviews indicate that probiotics containing *L. acidophilus* strains, including CUL60, significantly reduce the incidence of AAD compared to placebo, with some meta-analyses showing a relative risk reduction of 40-50% [1, 4]. This benefit is particularly relevant for individuals undergoing antibiotic treatment. In the context of irritable bowel syndrome (IBS), probiotic combinations that include *L. acidophilus* strains have demonstrated beneficial effects on global IBS symptoms, including abdominal pain and normalization of bowel habits, with some RCTs showing statistically significant symptom relief over placebo [3]. Furthermore, a 6-month randomized controlled trial using the Lab4P formulation (which includes *L. acidophilus* CUL60) in overweight adults showed significant reductions in body weight and small dense LDL cholesterol, suggesting a potential role in modulating cardiovascular risk factors [2]. These benefits typically manifest over weeks to months of consistent supplementation, with studies ranging from 4 weeks to 6 months in duration.

How it works

*Lactobacillus acidophilus* CUL60 primarily exerts its beneficial effects by colonizing the gut mucosa, where it competes with pathogenic bacteria for nutrients and adhesion sites. It produces lactic acid, which lowers the intestinal pH, creating an unfavorable environment for the growth of many harmful bacteria. This strain also modulates immune responses through interactions with gut-associated lymphoid tissue, potentially reducing inflammation and enhancing the integrity of the mucosal barrier. Additionally, *L. acidophilus* CUL60 may influence lipid metabolism through its bile salt hydrolase activity, which can contribute to improved cholesterol profiles. The strain is delivered as viable colony-forming units (CFU), and its efficacy depends on its survival through the harsh acidic conditions of the stomach and bile in the small intestine; encapsulation and refrigeration are often employed to enhance its viability.

Side effects

*Lactobacillus acidophilus* CUL60 is generally considered safe and well-tolerated for healthy adults and most patient populations. High-quality randomized controlled trials have not reported any serious adverse events associated with its use [2, 3, 4]. The most common side effects, if they occur, are mild and transient gastrointestinal symptoms such as bloating or gas, affecting less than 5% of users. These symptoms typically subside as the body adjusts to the probiotic. There are no significant drug interactions or contraindications specifically documented for *L. acidophilus* CUL60. However, as with all probiotics, caution is advised when administering to severely immunocompromised individuals, such as those with central venous catheters or severe underlying diseases, due to a theoretical risk of bacteremia, although this is extremely rare with *Lactobacillus* species. Pregnant and breastfeeding women should consult a healthcare professional before use, though probiotics are generally considered safe in these populations.

Dosage

Effective dosages of *Lactobacillus acidophilus* CUL60 in clinical trials typically range from 1 × 10^9 to 5 × 10^10 Colony Forming Units (CFU) per day. This is often administered as part of multi-strain probiotic capsules. For specific applications, such as the prevention of antibiotic-associated diarrhea (AAD), doses around 2 × 10^10 CFU daily have been used effectively [4]. The timing of supplementation can vary, but it is often recommended to take probiotics with food to enhance survival through the digestive tract. The duration of supplementation depends on the intended benefit; for acute conditions like AAD, it may be taken concurrently with antibiotics and for a short period afterward, while for chronic conditions like IBS or metabolic support, consistent use for 4 weeks to 6 months is often necessary to observe sustained benefits. To maintain the viability and potency of the bacterial cultures, refrigeration is generally recommended for products containing *L. acidophilus* CUL60.

FAQs

Is *L. acidophilus* CUL60 effective alone or only in combination?

Most evidence for *L. acidophilus* CUL60's benefits comes from multi-strain probiotic formulations. While it is a key component, its isolated effects require further dedicated study to fully understand its individual efficacy.

How soon can benefits be expected?

Symptom improvements may begin within a few weeks of consistent use. However, for more significant and sustained benefits, particularly for chronic conditions like IBS or metabolic effects, longer-term use, typically ranging from 1 to 6 months, is often required.

Is it safe during antibiotic use?

Yes, *L. acidophilus* CUL60 is commonly used and considered safe during antibiotic therapy. It is often recommended to prevent antibiotic-associated diarrhea, ideally starting within 36-48 hours of antibiotic initiation and continuing for a period after the antibiotic course ends.

Research Sources

https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2022.983075/full – This systematic review and meta-analysis found that probiotics containing *L. acidophilus* significantly reduce the incidence of diarrhea compared to placebo. The study highlighted a consistent effect across various populations and probiotic formulations, supporting the use of *L. acidophilus* for diarrhea prevention.
https://www.nature.com/articles/s41598-020-60991-7 – This double-blind, randomized controlled trial involving 105 overweight adults demonstrated that supplementation with the Lab4P probiotic, which includes *L. acidophilus* CUL60, led to significant reductions in body weight and small dense LDL cholesterol over a 6-month period, suggesting metabolic benefits.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10651259/ – This systematic review focused on probiotics for IBS patients and concluded that combinations including *L. acidophilus* improved global IBS symptoms and abdominal pain compared to placebo. The findings, while showing some variability in strains and doses, consistently pointed to beneficial effects for IBS management.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3925990/ – This systematic review investigated probiotics for antibiotic-associated diarrhea (AAD) and found that the LAB4 probiotic, containing *L. acidophilus* CUL60, reduced AAD incidence by approximately 40-50% compared to placebo. The evidence supports the efficacy of this strain combination in preventing AAD.